Lonza Group AG (OTCMKTS:LZAGY – Get Free Report) saw a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 7,100 shares, a decline of 49.3% from the February 13th total of 14,000 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 53,200 shares, the short-interest ratio is presently 0.1 days.
Wall Street Analysts Forecast Growth
Separately, Redburn Atlantic raised Lonza Group to a “strong-buy” rating in a report on Wednesday, November 27th.
View Our Latest Analysis on Lonza Group
Lonza Group Stock Up 1.9 %
Lonza Group Company Profile
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments.
Further Reading
- Five stocks we like better than Lonza Group
- 3 Small Caps With Big Return Potential
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What is the NASDAQ Stock Exchange?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.